Editor of Patient Care Online.
New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV
Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.
Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose
Your daily dose of the clinical news you may have missed.
Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease
Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose
Obesity & Chronic Pain Management: An Expert Discussion
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
Primary Care-Based Injury Prevention Program Reduces Pediatric Injuries: Daily Dose
FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
Atogepant vs Rimegepant for Migraine Prevention: Daily Dose
Obesity and Venous Disease: Expert Details Optimal Treatment Options
Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.
ADHD Stimulant Use Raises Risk of Cardiomyopathy in Young Adults: Daily Dose
Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data
ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.
Vaping Linked to Higher Risk of Heart Failure: Daily Dose
Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose
7 Drugs Approved for Primary Care: Q1 2024
The end of another quarter means a new list of FDA-approved drugs for conditions treated in primary care. Are you up-to-date? Click through to find out.
Primary Care-Based Injury Prevention Program Found to Reduce Pediatric Injuries in New Study
The program, when implemented with support of resident training and tangible tools, reduced parent-reported injuries throughout the first 2 years of life.
T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose
FDA Clears First AI-Based Algorithm to Detect Heart Failure during Routine Exams
The Low EF AI is designed to detect low ejection fraction in 15 seconds during a primary care exam.
FDA Approves Fixed-Dose Macitentan/Tadalafil Tablets for PAH: Daily Dose
Vaping Associated with Increased Risk of Heart Failure, According to New Research
ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.
Sustained LDL-C Control in High-Risk Group via Remote Lipid Program: Daily Dose
Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy
ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.
Disparities in Coronary Artery Calcium Screening: Daily Dose
Influenza Vaccine Education in Emergency Departments Improves Uptake, According to New Study
Investigators found vaccine uptake of 41% among unvaccinated individuals who were part of a messaging intervention in the emergency department.
FDA Approves Aprocitentan for Treatment-Resistant HTN: Daily Dose
Blood-Based DNA Test for Colorectal Cancer: Daily Dose
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Self-Administered Flu Vaccine May be “Powerful Tool” in Immunization Efforts, Says Expert
Ravi Jhaveri, MD, provides an overview of AstraZeneca's FluMist Quadrivalent vaccine and discusses why it could help increase vaccination rates.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.